Pharma Regulatory Affairs and EAEU Market Access in 2026: From Registration to Post-Market Surveillance
From Formula to Pharmacy Shelf
Every day, millions of people buy medicines, vitamins, and skincare products. Few stop to wonder why one specific drug is available at the pharmacy while another is not. The answer: the former passed registration, the latter did not.
This is what Regulatory Affairs (RA) handles. Specialists in this field prove to the state that a product is safe, of adequate quality, and performs exactly as the manufacturer claims. Without their work, not a single pill, medical device, or jar of baby food reaches the legal market.
January 2026 brought a turning point for the profession. As of January 1, the transition period for medicines within the Eurasian Economic Union (EAEU) officially closed.
The Union comprises five states: Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan. All pharmaceutical products must now comply with the unified requirements of all five countries. National Marketing Authorizations issued under the old rules of Russia, Kazakhstan, or Belarus no longer grant the right to release new batches to market.
The regulatory specialist has evolved from a «person with a folder of documents» into a strategic function that determines whether a product enters market on time and at acceptable cost.
The Three Requirements for Any Product
All health-related legislation rests on the same foundation: protect citizens from dangerous, low-quality, or useless products. Every medical commodity must meet three criteria.
Safety means the product does not cause unacceptable harm. No medicine is absolutely safe — every drug has side effects. The regulator’s task is ensuring that benefits outweigh risks. A headache tablet that causes heart attacks in one out of ten patients will not pass registration. The same side effect occurring in one in a million, where the drug treats a fatal disease, produces a different calculation.
In practice, safety assessment includes pre-clinical studies on animals and clinical trials on human volunteers. For medicines in the EAEU, this data occupies entire modules of the registration dossier — Module 4 for pre-clinical data, Module 5 for clinical data. The safety documentation for a single drug can run to tens of thousands of pages.
Quality means every package contains exactly what the label says. A tablet must contain the declared dose of the active substance. A cream must maintain its properties throughout its shelf life. A syringe must be sterile. Laboratory tests confirm quality: identification, quantitative content, purity, dissolution. Manufacturing sites undergo GMP compliance inspections.
From 2026, quality requirements are harmonized across the EAEU. The Union Pharmacopoeia establishes unified analytical methods and specifications. A manufacturer who previously used different methodologies for Russia and Kazakhstan now applies the same standards across all five countries.
Efficacy means the product does what it claims. If packaging states «lowers blood pressure,» the drug must actually lower it. Original medicines demonstrate this through clinical trials with hundreds or thousands of patients. For generic medicines, bioequivalence studies are sufficient — confirming that the generic medicine behaves in the body the same way as the original.
For medical devices, efficacy requirements depend on risk class. A simple bandage requires no clinical investigation; an implantable pacemaker undergoes years of research involving patients.
Remove any of these three elements and the system breaks. A safe, quality-compliant but ineffective drug occupies shelf space and blocks patient access to working treatment. An effective, quality-compliant but dangerous drug harms people. An effective, safe but poorly manufactured product works sometimes and sometimes does not.
The Product Lifecycle Through the Eyes of a Regulatory Specialist
Regulatory Affairs accompanies a product through every stage of its existence. The process runs continuously for as long as the drug remains on the market.
At the development stage, the regulatory specialist advises scientists: which tests registration will require, what documents must be provided, what requirements apply in target markets. An error at this stage can cost a company years and tens of millions of rubles. Clinical trials conducted with an incorrect design will not be accepted by the regulator — the process starts from scratch.
Regulatory strategy is defined at this stage: which markets to enter first, which procedure to use, how to reduce research costs. Since 2026, data from clinical trials conducted in any EAEU country under the Union’s GCP rules is accepted across all five member states. A bioequivalence study in Kazakhstan may cost considerably less than the same study in Russia.
During pre-clinical and clinical research, the regulatory specialist monitors compliance. Animal experiments follow GLP (Good Laboratory Practice) standards. Human trials comply with GCP (Good Clinical Practice) rules. These rules protect study participants and ensure the reliability of results. Research conducted with violations will not be accepted by the regulator, regardless of how strong the findings appear.
At the registration stage, the specialist compiles the dossier and submits it to the regulatory authority. For EAEU medicines, this is a registration dossier in CTD (Common Technical Document) format — five modules covering administrative information, quality, safety and efficacy summaries, quality documentation, pre-clinical reports, and clinical reports. A full dossier for an original drug can exceed one hundred thousand pages.
Regulatory experts review the documents and decide whether to issue a Marketing Authorization (MA). EAEU timelines depend on the chosen procedure: 160 working days in the Reference Member State for mutual recognition; comparable timelines for the decentralized procedure. In practice, requests for additional information routinely stretch the process to one and a half to two years.
At the production stage, the regulatory specialist ensures the manufacturing site complies with GMP (Good Manufacturing Practice) standards. Sites undergo inspections, and products cannot be released without a positive conclusion. The EAEU operates on mutual recognition of inspections: a site that passed inspection in Russia is accepted in Kazakhstan and other Union countries.
Since 2026, GMP inspections became a mandatory registration condition for all EAEU medicines. Previously, certain drug categories allowed a manufacturer’s written commitment to comply with standards. That option is gone: no inspection, no registration.
At the post-market stage, work does not stop. The pharmacovigilance system collects safety data identified during mass use. Rare complications sometimes emerge only after millions of patients have taken a drug. The regulatory specialist prepares PSURs (Periodic Safety Update Reports), amends the package leaflet, and in severe cases initiates market withdrawal.
Since 2026, unified pharmacovigilance rules — GVP (Good Vigilance Practice) — apply across the EAEU. Every MA holder must appoint a QPPV (Qualified Person for Pharmacovigilance) who bears personal responsibility for collecting and analyzing safety data. The adverse reaction database is now unified across the entire Union.
Regulated Sectors: From Tablets to MRI Machines
Regulatory principles are universal; the specific rules vary by product type. In 2026, Russia and the EAEU operate under distinct regimes for several categories.
Medicines go through the strictest procedure. The regulators are the Russian Ministry of Health at the national level and the Eurasian Economic Commission (EEC) at the EAEU level. From January 1, 2026, all new medicines are registered exclusively under the EAEU procedure. National procedures are no longer available.
For drugs registered under national rules before 2026, a «bringing into compliance» mechanism applies. Companies that submitted an application before December 31, 2025 retain their national MA during the expertise period, for a maximum of three years. If no application was filed, the MA is annulled and new batches cannot be released. Batches produced before January 1, 2026 may be sold until their expiration date.
Medical devices are regulated by Roszdravnadzor in Russia. At the EAEU level, the transition period continues until December 31, 2027. From January 1, 2026, new applications are submitted only under EAEU rules, but national MAs with unexpired validity remain in force.
Registration complexity depends on risk class. Class 1 devices (bandages, crutches) follow a simplified procedure. Classes 2a, 2b, and 3 (from blood pressure monitors to implants) require expert review and, for higher classes, clinical investigation. Quality Management System (QMS) inspections have become a serious bottleneck in 2026 — the queue for inspections reaches 12–18 months.
Dietary supplements (BAA) are registered by Rospotrebnadzor. They go through state registration and receive a State Registration Certificate (SRC). Requirements are lighter than for medicines: clinical efficacy studies are not required, but toxicological studies must confirm safety. Since 2026, supplements require mandatory labeling in the Chestny ZNAK system. Without a Data Matrix code, products cannot be sold at retail.
Cosmetics fall under Technical Regulation TR CU 009/2011. Most products require only a Declaration of Conformity, which the manufacturer issues independently based on test reports. Certain categories — children’s cosmetics, intimate hygiene products, and hair dyes — require state registration. In 2026, prohibited ingredient lists were updated and harmonized with European regulations; the CMR substance ban (carcinogenic, mutagenic, and reprotoxic compounds) is now synchronized with EU rules.
Veterinary medicines fall under Rosselkhoznadzor. Requirements resemble those for human medicines, with one specific addition: Maximum Residue Levels (MRLs) in livestock products. Since January 10, 2026, new standards under EEC Council Decision No. 70 set residue limits for 75 veterinary drugs in meat and milk.
Table 1: Regulated Product Categories in Russia and the EAEU (2026)
| Category | Regulator in Russia | Main Document | Transition Period |
|---|---|---|---|
| Medicines | Ministry of Health / EEC | Marketing Authorization | Ended Dec 31, 2025 |
| Medical Devices | Roszdravnadzor | Marketing Authorization | Until Dec 31, 2027 |
| Dietary Supplements | Rospotrebnadzor | State Reg. Certificate | Not applicable |
| Cosmetics | Rospotrebnadzor | Declaration / SRC | Not applicable |
| Veterinary Medicines | Rosselkhoznadzor | Marketing Authorization | Specific timelines |
Good Practices: The Language of the Industry
Regulatory Affairs relies on a system of international standards called Good Practices (GxP). Developed over decades, these rules define how to correctly execute every stage of work with a product.
GMP (Good Manufacturing Practice) sets requirements for production — from personnel qualification to air purity in manufacturing areas, from equipment validation to raw material control. The goal is eliminating the human factor and guaranteeing that every batch is identical to what was approved at registration. EAEU GMP rules (EEC Council Decision No. 77) are harmonized with EU rules and WHO recommendations. A manufacturing site compliant with EAEU GMP generally satisfies European requirements as well.
GCP (Good Clinical Practice) governs clinical trial conduct. These rules protect the rights of patients in trials and ensure data reliability. Core principles: voluntary informed consent, ethics committee approval, independent monitoring, and documentation of every procedure. Since 2026, EAEU-unified GCP rules allow trial data from any of the five member states to be accepted for registration in all of them.
GLP (Good Laboratory Practice) sets standards for pre-clinical research — experiment documentation, equipment calibration, personnel training, sample storage. A GLP-compliant laboratory can demonstrate that its results are reproducible and reliable.
GDP (Good Distribution Practice) defines requirements for transportation and storage. A perfectly manufactured medicine can be degraded by poor shipping: temperature excursions, light exposure, moisture. GDP ensures quality is maintained from factory to patient.
GVP (Good Vigilance Practice) establishes rules for post-market safety monitoring. Pharmacovigilance collects and analyzes adverse reaction data, identifies new risks, and initiates label changes or withdrawals when needed.
All five practices are interconnected. A failure in any one of them can compromise the entire product.
Digital Technologies in Regulatory Affairs, 2026
The regulatory sphere is moving rapidly onto digital infrastructure. Two directions define the 2026 agenda: electronic dossier formats and the regulation of AI-powered medical software.
Electronic dossiers (eCTD) have become the standard in most developed jurisdictions. The eCTD (electronic Common Technical Document) format is a structured set of metadata-tagged files that allows regulators to work through documentation efficiently. Europe, the United States, and Japan are transitioning to eCTD 4.0, built on an XML model with two-way communication between applicants and agencies.
The EAEU uses its own electronic submission format, described in EEC Board Decision No. 79. It includes XML application and document inventory files but is not fully compatible with the global eCTD 4.0 standard. Companies operating simultaneously in EAEU and EU markets must maintain two parallel dossier preparation systems.
AI-powered software (SaMD — Software as a Medical Device) is regulated in 2026 nearly as strictly as medicines. Roszdravnadzor in Russia has implemented automated monitoring of AI systems; developers of diagnostic algorithms must transmit technical performance logs for their products. In the EU, AI Act requirements for high-risk systems take full effect in August 2026. Medical devices with AI face dual conformity assessment: MDR for safety and efficacy as a medical device, and the AI Act for algorithm transparency, data quality, and bias. The additional regulatory burden comes with a corresponding increase in market credibility.
Why Regulatory Affairs Became a Critical Business Function
For years, many companies treated the regulatory department as a support unit. Scientists developed the formula, marketers planned the sales, and regulatory specialists somewhere at the end of the chain «processed the paperwork.» That model stopped working.
Regulatory strategy now determines market outcomes. A correctly chosen registration route saves a company six to twelve months and tens of millions of rubles. An incorrect choice can prevent the product from reaching market at all, or deliver it late, when competitors have already established themselves.
In the EAEU context, the stakes are higher still. A single dossier error can block access to five countries with a combined population over 180 million. Selecting the Reference Member State, planning a mutual recognition or decentralized procedure, coordinating with authorized representatives in multiple countries — all of this demands strategic thinking and an understanding of both regulatory requirements and commercial priorities.
A product recall triggered by regulatory violations carries not only direct financial losses but reputational damage that cannot be quantified easily. Large pharmaceutical companies invest heavily in regulatory compliance systems precisely because the cost of error is too high.
For manufacturers, a strong regulatory function has become a competitive advantage. Companies with capable regulatory teams bring products to market faster, spend less correcting errors, and respond more effectively to legislative changes. For generics, speed of entry after patent expiry can determine whether a company captures a substantial market share or arrives after the position is occupied.
For Those New to the Field
Start with the basic vocabulary. Learn the core abbreviations: MA (Marketing Authorization), RLA (Regulatory Legal Act), CTD, GMP, GCP, GLP, GDP, GVP. Without this foundation, professional literature is nearly inaccessible.
Define your segment early. Medicine regulation and cosmetics regulation differ as much as surgery and dentistry. Deep knowledge of one area is worth more than a surface familiarity with all of them. Choose a direction that matches your work or interests, then go deep.
Read the primary legal texts. For EAEU medicines, this is EEC Council Decision No. 78 of November 3, 2016 on rules for the registration and expertise of medicines. For medical devices: Decision No. 46 of February 12, 2016. Both are publicly available at eec.eaeunion.org. For Russian national law, the foundation is Federal Law No. 61-FZ of April 12, 2010 «On the Circulation of Medicines.»
Track changes actively. Healthcare legislation shifts constantly. Subscribe to newsletters from the Ministry of Health and Roszdravnadzor; follow industry publications such as Pharmaceutical Bulletin (Farmatsevtichesky vestnik) and Remedium; attend industry conferences. Regulatory changes can reshape ongoing projects overnight — finding out after the fact means lost time and money.
Apply knowledge to real cases. Regulatory Affairs is learned most effectively through actual tasks. If you work at a pharmaceutical company, ask colleagues in the regulatory department to walk you through a dossier structure or explain the logic of a current project. If you are building toward this career, seek internships or junior specialist positions. Theory without practice fades quickly.
As of January 2026, the EAEU pharmaceutical market operates under unified rules. The ten-year transition period has ended and national alternatives are gone. For medical devices, the transition runs until the end of 2027, but the direction is clear: harmonized requirements, digital processes, tighter oversight.
For professionals, this means mastering supranational legislation, working fluently with digital tools, and understanding the logic of adjacent markets — EU, FDA. For companies, the regulatory function has stopped being auxiliary. It now controls access to a market of five countries.
Sources: EEC Council Decision No. 78, November 3, 2016 — Rules for the Registration and Expertise of Medicines for Medical Use; EEC Council Decision No. 77, November 3, 2016 — EAEU Good Manufacturing Practice Rules; EEC Council Decision No. 46, February 12, 2016 — Rules for the Registration and Expertise of Medical Devices; EEC Council Decision No. 70 — Maximum Residue Levels for Veterinary Medicinal Products; EEC Board Decision No. 79, September 22, 2017 — General Requirements for Electronic Documents of the Registration Dossier; Federal Law No. 61-FZ, April 12, 2010 — On the Circulation of Medicines; Technical Regulation TR CU 009/2011 — On the Safety of Perfumery and Cosmetic Products.
Other articles on Regulatory Affairs →